Sep 27, 2010 by Brian Orelli, PhDBetter Buy: Ariad Pharmaceuticals or Corcept Therapeutics?A battle of drugless companies looking for their first hit.
Sep 27, 2010 by Brian Orelli, PhDThis Recall Is Different -- In a Good WayJohnson & Johnson strikes again, but it's not so bad this time.
Sep 27, 2010 by Brian Orelli, PhDNow That's What I Call a Drug That WorksSeattle Genetics hits a home run -- and then some.
Sep 24, 2010 by Brian Orelli, PhDThese Companies Smile at Avandia's WoesLosers and winners are like yin and yang.
Sep 24, 2010 by Brian Orelli, PhDSo Long and Thanks for All the Drug CandidatesAlnylam and Novartis end their five-year partnership.
Sep 24, 2010 by Brian Orelli, PhDGood Deal? Bad Deal? Hard to Tell.Investors are in the dark on this one.
Sep 24, 2010 by Brian Orelli, PhDPrepare for This $12 Billion WhooshLipitor going generic leaves a hole, but be careful filling it.
Sep 23, 2010 by Brian Orelli, PhDUgly Side Effects Won't Derail This DrugSide effects don't matter much when there are no other treatment options.
Sep 23, 2010 by Brian Orelli, PhDA Blockbuster in Due TimeNovartis' new multiple sclerosis drug, Gilenya, isn't king yet.
Sep 22, 2010 by Brian Orelli, PhDBetter Buy: Amylin Pharmaceuticals or MannKind?It's a diabetes-drug showdown.
Sep 22, 2010 by Brian Orelli, PhDA Dendreon Deal: It's Not What You ThinkDendreon gets help manufacturing Provenge, but there's still work ahead.
Sep 21, 2010 by Brian Orelli, PhDAn Acquisition Helps Boston Scientific Breathe EasierBoston Scientific diversifies by picking up device maker Asthmatx.
Sep 21, 2010 by Brian Orelli, PhDDouble-Digit Weight Loss, Double-Digit Share IncreaseVivus is down, but apparently not out.
Sep 20, 2010 by Brian Orelli, PhDPotential Blockbuster, No Me-Too About ItA diabetes-fighting duo do it right this time.
Sep 17, 2010 by Brian Orelli, PhDThanks for Nothing, Fen-PhenArena gets knocked down despite a relatively clean side-effect profile.
Sep 17, 2010 by Brian Orelli, PhDJohnson & Johnson: More Buffett-Like Every DayFirst you invest in the company; then you buy the whole shebang.
Sep 16, 2010 by Brian Orelli, PhDAbbott's Product Line May Get ThinnerNot that it needs the obesity drug.
Sep 15, 2010 by Brian Orelli, PhDCell Therapeutics Goes for BrokeIt's an understatement to say it's trying a Hail Mary.
Sep 15, 2010 by Brian Orelli, PhDDrug Approved. Now Let's Sell This Baby!With ink still wet on its FDA approval, Savient continues its plan to find a buyer.
